← Map · Health Care Equipment · S&P MidCap 400
PEN PENUMBRA
Yes — algorithm is the offer. Pending BSX deal
What they are doing
Thrombectomy company whose product is computer-assisted vacuum thrombectomy (CAVT): microprocessor algorithms that detect clot versus blood flow and modulate aspiration (Lightning Flash, Lightning Bolt). That is the offer, same shape as Tandem's algorithm. Pending Boston Scientific deal (14 Jan 2026, about $14.5B, expected close in 2026). No Q2 strategy call. STORM-PE is a device / procedure result — do not treat it as an algorithm KPI.
Why the score
- Reach 3 not 2: CAVT is a live program across venous / PE / arterial.
- Weight 3 not 4: the algorithm is how they sell clot removal. 4 waits for a result this snapshot (deal quiet).
- Proof 3 not 4: live CAVT we can point to. No current algorithm KPI.
What would move it next quarter: The deal is the equity story now. If it breaks, we want an algorithm KPI — not another catheter print.
Open these first
Evidence
CAVT algorithms detect the difference between thrombus and patent flow and automatically adjust vacuum from the Penumbra ENGINE. Lightning Flash and Lightning Bolt portfolios.
Merger Agreement with Boston Scientific dated 14 Jan 2026. $374 per share, about $14.5B enterprise value. Expected close in 2026, still pending as of 30 Jun 2026.